Value-based contracts can lower costs for payers, offer pharmaceutical companies valuable feedback about their therapies, and, ultimately, improve the quality of health care.
Jorge E. Galva, JD, MHA, Executive Director at ASES
Advertisement
Articles by Jorge E. Galva, JD, MHA, Executive Director at ASES
Advertisement
Latest Updated Articles
Partnerships Between Medicaid Programs and PBMs Will Shape Future of Health CarePublished: February 1st 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
4
Interim Phase 2 IOV-LUNG-202 Data Show Lifileucel’s Potential Treating Advanced NSCLC
5
